Development of Eye Drop for AMD

"/
Age-related Macular Degeneration (AMD) is the leading cause of blindness among the elderly. The most commonly used drugs to slow the progression of the disease is Roche’s Lucentis and Regeneron’s Eylea. These drugs are injected into the eye which, needless to say, leads to more inconvenience.
Scientists from Birmingham University have developed an alternative treatment in the form of eye drops. These eye drops consists of a peptide which could penetrate retinal cells. After testing the eye-drops and rabbits and pigs, the results were reported in Investigative Ophthalmology & Visual Science journal. These eye drops are currently being developed in a U.S. startup company named Macregen.
Felicity de Cogan, a research fellow from the University of Birmingham’s Institute of Microbiology and Infection, said "From the outset, we [realized] that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.”
Lucentis and Eylea inhibit the VEGF protein, and plugs up the leaky blood vessels. In a partnership project, Regeneron tried to combine its drug with the Bayer antibody nesvacumab, but the results were disappointing and the trails were ended.
Macregen and the Birmingham University team are planning to start clinical trials of the eye drops next year, possibly as early as spring.
The post Development of Eye Drop for AMD appeared first on Drugdu.com
from Drugdu  https://goo.gl/QgQoHk
By Ddu

评论

发表评论

此博客中的热门博文

NuVasive gets FDA Approval for Pulse Spinal Surgical Automation Platform

图片
The San Diego-based company NuVasive has announced US-FDA 510(k) clearance for its Pulse spinal surgical automation platform. The platform includes 2D and 3D navigation and smart imaging capabilities, with implemented surgical planning, neuromonitoring, patient-specific rod bending tech and radiation reduction. Dr. Stephen Ryu of the Palo Alto Medical Foundation said,  “Pulse seamlessly integrates multiple intraoperative technologies through an intuitive guided surgical workflow within a single device and footprint in the operating room. Unlike other newer surgical technologies, Pulse enhances the surgeon’s ability and can positively affect outcomes by providing a modular platform of useful intraoperative tools that do not disrupt familiar workflow. Additionally, Pulse provides enhanced support throughout each case be it a simple decompression all the way to complex deformity cases.” The platform has been integrated with a ...
阅读全文

New Version of Fitbit, Charge 3, Features Spo2 Tracking

图片
A new member has been added to the Fitbit Charge Family namely the Fitbit Charge 3 with an additional feature of measuring the SpO2. The new version will hit the market in October.  “ With Charge 3, we are building on the success of our best-selling Charge franchise and delivering our most innovative tracker, offering an extremely slim, comfortable, and premium design, along with the advanced health and fitness features our users want. Charge 3 gives existing users a compelling reason to upgrade, while also allowing us to reach new users who want a sleeker, more affordable wearable in a tracker form factor ,” CEO Fitbit James Park said in a statement. The new version claims to identify indicators of allergies, asthma, or sleep apnea with its relative SpO2 tracker which enables the device to assess variations in blood oxygenation levels and spot breathing abnormalities. As included in its Pre-Cert pilot, aiming to develop FDA-monitored software for illnesses like sleep apne...
阅读全文

New Biomarker to Prevent Severe Bouts of Low Blood Sugar in Diabetics

图片
A new biomarker might possibly furnish new clues required to develop a diagnostic tool for hypoglycemia-associated autonomic failure (HAAF), an LSU Pennington Biomedical Research Center study found. There is no current objective diagnostic device for this life-threatening condition, if unchecked. "There is currently no objective way for a health care provider to measure whether a patient has experienced repeated episodes of low blood sugar and therefore may be suffering from HAAF," said David McDougal, Ph.D., assistant professor-research and head of Pennington Biomedical's Neurobiology of Metabolic Dysfunction Laboratory. Researchers at LSU Pennington Biomedical aimed to find ways via which biomedical imaging could present new solutions that enable measurement of occurrence of glucose level collapse. Instead of looking at glucose uptake in the directly in the brain, they focused on the adaptation of the brain after an incidence of crashed glucose leve...
阅读全文